

# Better Asthma Treatment: Monitoring with ACT and Nitric oxide.

Gepubliceerd: 08-09-2009 Laatste bijgewerkt: 18-08-2022

This study aims to answer two research questions: 1. Does web-based monthly monitoring using the Asthma Control Test (ACT) improve asthma control? Is this strategy cost-effective? 2. Does asthma management guided by the fraction of nitric oxide in...

<b>Ethische beoordeling</b>	Positief advies
<b>Status</b>	Werving gestopt
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON26506

### Bron

Nationaal Trial Register

### Verkorte titel

BATMAN study

### Aandoening

Asthma control, monitoring, children, exhaled nitric oxide

### Ondersteuning

**Primaire sponsor:** Erasmus Medical Center, Sophia Children's Hospital, Department of Pediatric Pulmonology

**Overige ondersteuning:** Astmafonds

ZonMW

Fonds NutsOhra

### Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

Primary endpoint is the proportion of symptom free days (SFD) during the 4 weeks before the final visit (t =12 months).

## Toelichting onderzoek

### Achtergrond van het onderzoek

Rationale: Asthma affects approximately 150.000 children in the Netherlands. Despite the availability of effective treatment, 30-50% of children with asthma are poorly controlled. This project will compare the effect on paediatric asthma control of two innovative monitoring strategies in comparison to usual care.

Objectives: This study aims to answer two research questions:

1. Does web-based monthly monitoring using the Asthma Control Test (ACT) improve asthma control? Is this strategy cost-effective?
2. Does asthma management guided by the fraction of nitric oxide in exhaled air (FENO) improve asthma control? Is this strategy cost-effective?

We hypothesize that both strategies are superior to usual care, with more symptom free days (SFD) during the last 4 weeks of the study.

Study design: This is a prospective, controlled, multi-centre study, in which 300 children will be randomly allocated to 1 of 3 treatment algorithms.

Study population: 300 children, 4 -18 yrs, with allergic asthma and using ICS will be enrolled. Children and/ or their parents should have access to Internet at home. Exclusion criteria are active smoking, pulmonary conditions other than asthma and inability to perform FENO measurements.

Intervention: children will be randomly allocated to 1 of 3 treatment algorithms:

1. Control group: treatment according to national guidelines;
2. FENO group: FENO guides treatment;

3. Web group: an Internet program with monthly ACTs guides treatment.

Main study parameters/endpoints: Primary endpoint is the proportion of SFD during the last 4 weeks of the study. Secondary endpoints are: asthma related quality of life, patient utilities, costs, symptoms, use of rescue and controller medication, bronchial hyperresponsiveness, FENO, lung function, exacerbations, ICS dose.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation in this trial does not carry any risks and the burden to the patients is minimal. This study follows usual care as much as possible with a minimum of extra clinic visits (1-3 in 12 months). At every visit patients fill in the ACT, CostQ and EQ-5D (all short questionnaires). At the start and end of the study, in addition, lung function tests and bronchoprovocation tests will be performed and the paediatric asthma quality of life questionnaire (PAQLQ, 23 items) and strengths and difficulties questionnaire (SDQ) will be filled in. These 2 visits will last around 2.5 hours.

Patients and their parents will be asked to fill in diary cards during run-in, 2 weeks before visit  $t = 4$  months and  $t=8$  months and 4 weeks before the final visit. Diary cards address questions on symptoms, exercise tolerance and use of medication. Completing diary cards will cost 1-2 minutes every day.

Children in the web-arm fill in an ACT every 4 weeks (duration 2-3 minutes).

This study is performed in children as asthma is a highly prevalent disorder in children, and asthma in children differs from asthma in adults in several ways, including differing phenotypes, and assessment and monitoring of asthma control.

## **Doel van het onderzoek**

This study aims to answer two research questions:

1. Does web-based monthly monitoring using the Asthma Control Test (ACT) improve asthma control? Is this strategy cost-effective?
2. Does asthma management guided by the fraction of nitric oxide in exhaled air (FENO) improve asthma control? Is this strategy cost-effective?

We hypothesize that both strategies are superior to usual care, with more symptom free days (SFD) during the last 4 weeks of the study.

## **Onderzoeksopzet**

$t = -1$ ,  $t = 0$ , 4, 8 and 12 months.

## Onderzoeksproduct en/of interventie

Children will be randomly allocated to 1 of 3 treatment algorithms:

1. Control group: treatment according to national guidelines;
2. FENO group: FENO guides treatment;
3. Web group: an Internet program with monthly ACTs guides treatment.

## Contactpersonen

### Publiek

Erasmus Medical Center, Sophia Children's Hospital, Department of Pediatric Pulmonology  
Dr. Molenwaterplein 60  
T.A.S. Bergen, van  
Erasmus Medical Center, Sophia Children's Hospital, Department of Pediatric Pulmonology  
Dr. Molenwaterplein 60  
Rotterdam 3015 GJ  
The Netherlands  
+31 (0)10-4636263

### Wetenschappelijk

Erasmus Medical Center, Sophia Children's Hospital, Department of Pediatric Pulmonology  
Dr. Molenwaterplein 60  
T.A.S. Bergen, van  
Erasmus Medical Center, Sophia Children's Hospital, Department of Pediatric Pulmonology  
Dr. Molenwaterplein 60  
Rotterdam 3015 GJ  
The Netherlands  
+31 (0)10-4636263

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Children 4-18 years old with allergic asthma, using inhaled corticosteroids for at least 3

months preceding the study;

2. Children and/or their parents should have access to the Internet at home;
3. Children should be able to perform FENO measurements.

### **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Active smoking;
2. Chronic lung disease other than asthma;
3. Inability of parents or older children (>11 years) to read or understand Dutch.

## **Onderzoeksopzet**

### **Opzet**

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blindering:	Enkelblind
Controle:	Geneesmiddel

### **Deelname**

Nederland	
Status:	Werving gestopt
(Verwachte) startdatum:	01-12-2009
Aantal proefpersonen:	300
Type:	Werkelijke startdatum

## **Ethische beoordeling**

Positief advies	
Datum:	08-09-2009

Soort:

Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

Register	ID
NTR-new	NL1881
NTR-old	NTR1995
Ander register	METC Erasmus MC/Nationaal Astma Fonds projectnummer/ZonMw projectnummer : MEC-2009-164/3408039/171002101
ISRCTN	ISRCTN wordt niet meer aangevraagd.

## Resultaten

### Samenvatting resultaten

N/A